How Digital Biomanufacturing Is Transforming Viral Vector Manufacturing

This episode explores digital biomanufacturing of viral vectors and how it is transforming gene therapy manufacturing as cell and gene therapy pipelines scale globally. Drawing on insights from Frost & Sullivan, we examine why viral vector manufacturing has become a critical bottleneck and how digital transformation is reshaping speed, quality, and scalability. We discuss key trends in digital biomanufacturing, including intelligent manufacturing systems, real-time process monitoring, and data-driven optimization, alongside the integration challenges facing manufacturers today. The episode also highlights regional adoption dynamics, competitive pressures, and the role of collaboration in building resilient, scalable viral vector production ecosystems. 👉 Why viral vector manufacturing is limiting gene therapy scale 👉 How digital biomanufacturing technologies are improving efficiency and consistency 👉 Where regional digital maturity and partnerships will define future advantage Explore related research on gene therapy and biomanufacturing: https://www.frost.com | https://store.frost.com Connect with our team: hello@frost.com